SC
MRVI icon

Steven Cohen’s Maravai LifeSciences MRVI Stock Holding History

Steven Cohen’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$3.53M – 1546
2022
Q1 		$3.53M Buy
+100,000
New +$3.35M 0.01% 772

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Steven Cohen's MRVI Position: Q2 2026 in Review

Steven Cohen reduced its Maravai LifeSciences (MRVI) stake by 37% in Q2 2026, selling an estimated $5.18M and leaving 2,005,579 shares worth $12.5M. The position accounts for 0.01% of the portfolio, ranked #1145.

Steven Cohen first reported a position in MRVI in Q4 2020 and has held it in 13 quarters since. The position peaked at $25.2M in Q2 2024. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Steven Cohen held 2,005,579 shares of Maravai LifeSciences worth $12.5M as of Q2 2026.
  • Steven Cohen sold 1,199,917 Maravai LifeSciences shares in Q2 2026, an estimated $5.18M.
  • Maravai LifeSciences made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1145 holding.
  • Steven Cohen first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 13 quarters since.
  • Steven Cohen's Maravai LifeSciences position peaked at $25.2M in Q2 2024.
  • 177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.